Proceedings of International Conference on Applied Innovation in IT
2025/06/27, Volume 13, Issue 2, pp.729-736
Molecular Study of Multidrug-Resistant Integrons Associated with Acinetobacter baumannii Isolated from Clinical Samples
Ali Adel Abud Alhussein and Suaad Abid Fazaa Abstract: The study investigated the prevalence of class one, two, and three integrons in A. baumannii isolates obtained from patients admitted to government hospitals in Diwaniyah (General Diwaniyah, Women and Children, al Hussein, and Burns Hospital) in Al-Qadisiyah Governorate, Iraq. From September 2024 to January 2025, 150 non-duplicate samples were collected, including 21 (14%) wound swabs, 36 (24%) burn swabs, 32 (21.33%) blood samples, 34 (22.66%) urine samples, and 27 (18%) tracheal swabs. After initial identification on MacConkey agar, blood agar, and chromium agar, the samples were chemically tested and Gram-stained. The VITEK2 compact system was used to confirm the diagnosis. This study showed that 117 (78%) of the samples showed bacterial growth, of which 40 (34.18%) were confirmed as A. baumannii, distributed as follows: 3 isolates (14.28%) from wounds, 6 isolates (16.66%) from burn swabs, 13 isolates (40.62%) from blood, 6 isolates (17.64%) from urine samples, and 12 isolates (44.44%) from tracheal swabs. The data indicated that tracheal swabs had the highest percentage of A. baumannii isolation, followed by blood, urine, burns, and wounds (44.44%, 40.62%, 17.64%, 16.66%, and 14.28%, respectively). Antibiotic susceptibility testing was performed using the Vitek device for 20 antibiotics. The purity and concentration of genomic DNA were measured using a Nanodrop instrument, and a conventional PCR reaction was set up to detect integrons using specific primers provided by Promega. The products were analyzed by agarose gel electrophoresis. The highest prevalence was found for class I integrons (23 samples, 57.5%), followed by class III (9 samples, 22.5%), and class II (6 samples, 15%) out of the 40 A. baumannii-positive samples.
Keywords: Acinetobacter baumannii, Antibiotic Resistance, Multidrug Resistance, Integrons, Clinical Isolates.
DOI: Under Indexing
Download: PDF
References:
- H. Ejaz, M. Ahmad, S. Younas, K. Junaid, K. O. A. Abosalif, A. E. Abdalla, A. A. M. Alameen, M. Y. M. Elamir, S. N. A. Bukhari, N. Ahmad, et al., "Molecular epidemiology of extensively-drug resistant Acinetobacter baumannii sequence type 2 co-harboring bla(NDM) and bla(OXA) from clinical origin," Infect. Drug Resist., vol. 14, pp. 1931–1939, 2024.
- A. Chukamnerd, K. Singkhamanan, V. Chongsuvivatwong, P. Palittapongarnpim, Y. Doi, R. Pomwised, and K. Surachat, "Whole-genome analysis of carbapenem-resistant Acinetobacter baumannii from clinical isolates in Southern Thailand," Computational and Structural Biotechnology Journal, vol. 20, pp. 545–558, 2022.
- A. Pompilio, D. Scribano, M. Sarshar, G. Di Bonaventura, A. T. Palamara, and C. Ambrosi, "Gram-negative bacteria holding together in a biofilm: the Acinetobacter baumannii way," Microorganisms, vol. 9, p. 1353, 2021.
- L. R. Marks, R. M. Reddinger, and A. P. Hakansson, "Biofilm formation enhances fomite survival of Streptococcus pneumoniae and Streptococcus pyogenes," Infect. Immun., vol. 82, pp. 1141–1146, 2014.
- M. A. Horcajada, M. Monsalve, M. A. Reuter, J. R. Figueiredo, A. L. Dupont, D. Bladé, and J. Vila, "Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii clinical isolates in Barcelona, Spain," Antimicrob. Agents Chemother., vol. 56, no. 5, pp. 2766–2771, 2012.
- K. M. Lee, D. Y. Lee, and J. H. Jung, "Genomic analysis of Acinetobacter baumannii clinical isolates in South Korea: Resistance mechanisms and clonal diversity," Front. Microbiol., vol. 13, p. 834567, 2022.
- S. T. Peleg, H. Seifert, and D. L. Paterson, "Acinetobacter baumannii: Emergence of a successful pathogen," Clin. Microbiol. Rev., vol. 21, no. 3, pp. 538–582, 2008.
- M. T. Mohammed, A. K. Ali, and H. S. Al-Shuwaikh, "Detection of blaOXA-23-like and blaNDM-1 genes in multidrug-resistant Acinetobacter baumannii isolates from Iraq," New Microbes New Infect., vol. 43, p. 100915, 2021.
- A. R. Abdi, F. Karami, M. Azizi, and S. R. Shakibaie, "Phenotypic and genotypic characterization of biofilm formation in clinical isolates of Acinetobacter baumannii," Iran. J. Basic Med. Sci., vol. 21, no. 3, pp. 287–292, 2018.
- B. Harding, D. Henningsen, and T. Begun, "Carbapenem-resistant Acinetobacter baumannii: Epidemiology, clinical impact, and infection control," Curr. Opin. Infect. Dis., vol. 31, no. 4, pp. 364–372, 2018.
- C. F. Higgins, S. Overdevest, M. J. Riley, J. C. Boyce, and T. T. Nguyen, "Molecular mechanisms of resistance to colistin in Acinetobacter baumannii," J. Antimicrob. Chemother., vol. 73, no. 6, pp. 1539–1545, 2018.
- M. A. Durante-Mangoni, L. Andini, and G. Zarrilli, "Extensively drug-resistant Acinetobacter baumannii: Clinical impact and therapeutic options," Pathog. Dis., vol. 75, no. 5, pp. 1–8, 2017.
- T. Krizova, M. Dijkshoorn, L. Nemec, "Diversity and evolution of AbaR genomic resistance islands in Acinetobacter baumannii strains of European clone I," Antimicrob. Agents Chemother., vol. 55, no. 7, pp. 3201–3206, 2011.
- M. Kempf and H. Rolain, "Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options," Int. J. Antimicrob. Agents, vol. 39, no. 2, pp. 105–114, 2012.
- Y. Hu, Y. He, X. Zhang, Z. Wu, and G. Zhao, "Comparative genomic analysis reveals the evolution and genetic diversity of multidrug-resistant Acinetobacter baumannii," BMC Genomics, vol. 21, p. 239, 2020.
- J. R. Evans, T. Y. Tran, M. L. Smith, and K. A. Wilson, "Biofilm-related infections in Acinetobacter baumannii: Pathogenesis and therapeutic strategies," Front. Cell. Infect. Microbiol., vol. 10, p. 558, 2020.
- M. Vijayakumar, V. K. Prasanna, A. Murugan, and R. K. Kannan, "Molecular characterization of Acinetobacter baumannii clinical isolates in India: Multidrug resistance and biofilm formation," Indian J. Med. Microbiol., vol. 39, no. 1, pp. 32–38, 2021.
- N. Nowak, T. S. Seifert, and A. Higgins, "Clinical and economic burden of Acinetobacter baumannii infections in the ICU: A systematic review," Crit. Care Med., vol. 48, no. 12, pp. 1743–1751, 2020.
- G. Perez, R. J. Hujer, A. Marshall, D. M. Hujer, J. M. Domitrovic, and R. A. Bonomo, "Global challenge of multidrug-resistant Acinetobacter baumannii," Antimicrob. Agents Chemother., vol. 61, no. 6, e02591-16, 2017.
- C. Antunes, L. Visca, and H. Towner, "Acinetobacter baumannii: Evolution of a global pathogen," Pathog. Dis., vol. 71, no. 3, pp. 292–301, 2014.
- M. B. Wareham and D. J. Bean, "In vitro activity of colistin against multidrug-resistant Acinetobacter baumannii clinical isolates," Int. J. Antimicrob. Agents, vol. 33, no. 1, pp. 93–96, 2009.
|

HOME

- Conference
- Journal
- Paper Submission to Journal
- For Authors
- For Reviewers
- Important Dates
- Conference Committee
- Editorial Board
- Reviewers
- Last Proceedings

PROCEEDINGS
-
Volume 13, Issue 2 (ICAIIT 2025)
-
Volume 13, Issue 1 (ICAIIT 2025)
-
Volume 12, Issue 2 (ICAIIT 2024)
-
Volume 12, Issue 1 (ICAIIT 2024)
-
Volume 11, Issue 2 (ICAIIT 2023)
-
Volume 11, Issue 1 (ICAIIT 2023)
-
Volume 10, Issue 1 (ICAIIT 2022)
-
Volume 9, Issue 1 (ICAIIT 2021)
-
Volume 8, Issue 1 (ICAIIT 2020)
-
Volume 7, Issue 1 (ICAIIT 2019)
-
Volume 7, Issue 2 (ICAIIT 2019)
-
Volume 6, Issue 1 (ICAIIT 2018)
-
Volume 5, Issue 1 (ICAIIT 2017)
-
Volume 4, Issue 1 (ICAIIT 2016)
-
Volume 3, Issue 1 (ICAIIT 2015)
-
Volume 2, Issue 1 (ICAIIT 2014)
-
Volume 1, Issue 1 (ICAIIT 2013)

PAST CONFERENCES
ICAIIT 2025
-
Photos
-
Reports
ICAIIT 2024
-
Photos
-
Reports
ICAIIT 2023
-
Photos
-
Reports
ICAIIT 2021
-
Photos
-
Reports
ICAIIT 2020
-
Photos
-
Reports
ICAIIT 2019
-
Photos
-
Reports
ICAIIT 2018
-
Photos
-
Reports
ETHICS IN PUBLICATIONS
ACCOMODATION
CONTACT US
|
|